Aravax
Melbourne, AU · 20 employees on LinkedIn · 4 known investors
Find your way into Aravax
276 people in our graph share verified history with the Aravax team — schools, employers, funds. One of them is your warm intro.
Giovanni Mariggiunlockedknows Sara Prickett · together at Imperial College London (overlapped)
×3knows the team · via Imperial College London
×7knows the team · via The University of Sheffield
knows the team · via The Walter and Eliza Hall Institute of Medical Research
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.
Founders & leadership
SP
Sara PrickettinCo-founderSara Prickett is Chief Scientific Officer and Co-founder of Aravax, a clinical-stage biotechnology company developing immunotherapies for food allergies. She has held prior roles as Chief Operating Officer at Aravax and Senior Medical Research Scientist specializing in immunology, with research focused on understanding immune responses and translating findings into disease management approaches.
Investors · 4
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Aravax do?
- Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.
- Who founded Aravax?
- Aravax was founded by Sara Prickett.
- Who are Aravax's investors?
- Aravax's investors include Novartis Venture Fund, Tenmile, Breakthrough Victoria, UniSeed Pty Ltd..
- Where is Aravax headquartered?
- Aravax is headquartered in Melbourne, AU.